Form 4: Pulse Biosciences Director Acquires 200,000 Stock Options
SEC Form 4 Filing
Manmeet Singh Soni, a director of Pulse Biosciences, acquired 200,000 stock options on August 9, 2024.
Summary
- On August 9, 2024, Manmeet Singh Soni, a director of Pulse Biosciences, acquired 200,000 stock options.
- The exercise price of these options is $15.65.
- The options vest over a period of three years, with one-fourth vesting on the date of the Issuer's next annual meeting of stockholders and the remaining shares vesting monthly thereafter, contingent upon continued service.
- The options expire on August 9, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is neither inherently positive nor negative. It reflects typical executive compensation practices.
Future Outlook
The vesting schedule of the options is contingent upon the Reporting Person's continued service, suggesting an expectation of continued involvement with the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors. Option grants are a common form of executive compensation in the biotechnology industry.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule described (one-fourth at the next annual meeting, then monthly over three years) is a fairly typical arrangement designed to incentivize long-term commitment.
- Comparable companies in the biotech space, such as CRISPR Therapeutics or Intellia Therapeutics, also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- The acquisition of stock options by a director can signal confidence in the company's future prospects, potentially influencing shareholder sentiment.
- The vesting schedule incentivizes the director to remain with the company, which could benefit employees and other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of transaction: Director acquired 200,000 stock options. |
| 08/09/2024 | Date of vesting: One-fourth of the shares subject to the option will vest on the date of the Issuer's next annual meeting of stockholders. |
| 08/13/2024 | Date of signature on the Form 4 filing. |
| 08/09/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.